Description
Tesamorelin 20 mg — GHRH Analog for Visceral Fat & Endocrine Research
Tesamorelin is a synthetic growth hormone–releasing hormone (GHRH) analog
designed to stimulate endogenous growth hormone (GH) secretion via pituitary GHRH receptors.
In preclinical and clinical research, Tesamorelin has been studied for its effects on
visceral adipose tissue (VAT), body composition, and metabolic/endocrine markers,
particularly in settings of altered fat distribution.
What It Is
- Class: GHRH (growth hormone–releasing hormone) analog
- Concept: Mimics native GHRH signaling to increase pulsatile GH release and
secondarily influence IGF-1 and downstream metabolic endpoints. - Format: Research-grade synthetic peptide supplied as a lyophilized powder.
Proposed Mechanisms (Preclinical)
GHRH–Pituitary Axis
- Activates GHRH receptors on pituitary somatotroph cells.
- Engages cAMP/PKA signaling pathways linked to GH synthesis and secretion.
- Supports pulsatile GH release rather than continuous exogenous GH exposure.
Downstream Body-Composition Effects
- Research explores changes in visceral adipose tissue, trunk fat, and
overall body-composition indices. - Model-dependent effects on IGF-1 levels, lipid profiles, and metabolic markers.
- Interest in differentiation between subcutaneous vs. visceral fat responses.
Selected Research Highlights
- Visceral Fat Models: Tesamorelin has been studied for reductions in
visceral adipose tissue and changes in trunk/abdominal fat distribution in
select clinical populations. - Growth Hormone Axis: Investigations report increases in GH/IGF-1
parameters with GHRH analog exposure, with associated changes in body composition and
metabolic readouts. - Metabolic & Cardiovascular Markers: Research includes effects on
lipids, glucose control, and cardiovascular risk markers in model systems. - Aging & Endocrine Research: GHRH analogs are of interest in broader
studies of endocrine aging, anabolic–catabolic balance, and tissue repair.
Chemical & Handling Information
- Type: Synthetic growth hormone–releasing hormone analog
- Backbone: Modified GHRH(1–44)–type sequence with stabilizing substitutions
(exact sequence per specification/lot) - Appearance: White to off-white lyophilized powder
Specifications
- Peptide: Tesamorelin
- Amount: 20 mg per vial
- Form: Lyophilized powder
- Purity: ?99% (HPLC); COA per lot available
- Packaging: Sealed vials suitable for standard laboratory handling
Storage & Stability
- Store lyophilized vials in a cool, dry place, protected from light.
- Refrigeration or freezing of the lyophilized peptide is recommended for extended stability,
according to laboratory SOPs. - After reconstitution, store at 2–8 °C for short-term use.
- For long-term storage, aliquot and freeze at ?20 °C or below; avoid repeated freeze–thaw cycles.
Reviews
There are no reviews yet.